MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

582.19 -0.06

Buy Sell

Overview

Share price change

24h

Current

Min

580.39

Max

585.53

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+7.01% upside

Market Stats
By TradingEconomics
Market Cap	4.2B 13B
Previous open	582.25
Previous close	582.19

News Sentiment

By Acuity

50%

157 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 gru 2025, 22:20 UTC

Major Market Movers

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 gru 2025, 17:31 UTC

Major Market Movers

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 gru 2025, 16:30 UTC

Major Market Movers

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 gru 2025, 15:19 UTC

Major Market Movers

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 gru 2025, 15:17 UTC

Major Market Movers

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 gru 2025, 14:37 UTC

Major Market Movers

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 gru 2025, 21:13 UTC

Acquisitions, Mergers, Takeovers

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 gru 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 gru 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 gru 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 gru 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31 gru 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31 gru 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 gru 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 gru 2025, 17:16 UTC

Major Market Movers

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31 gru 2025, 17:00 UTC

Acquisitions, Mergers, Takeovers

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 gru 2025, 15:57 UTC

Acquisitions, Mergers, Takeovers

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 gru 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 gru 2025, 15:02 UTC

Major Market Movers

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 gru 2025, 14:40 UTC

Acquisitions, Mergers, Takeovers

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 gru 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31 gru 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31 gru 2025, 13:01 UTC

Earnings

Acquisitions, Mergers, Takeovers

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31 gru 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31 gru 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31 gru 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31 gru 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31 gru 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

7.01% upside

12 Months Forecast

Average 624.67 USD 7.01%

High 900 USD

Low 527 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

157 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.